Recruiting
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed - CA039-001
Aktualisiert:
19 November, 2021
|
ClinicalTrials.gov
Phase
Geschlecht(er)
Altersgruppe
Standort(e)
Recruiting
For more information regarding Bristol Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologically or cytologically confirmed advanced/metastatic solid tumor and refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant - IO therapy resistant or insensitive tumors - Have at least 2 tumor lesions accessible for biopsy - Eastern Cooperative Oncology Group Performance Status of 0 or 1 Exclusion Criteria: - Primary central nervous system malignancy - Participants with other active malignancy requiring concurrent intervention - Uncontrolled or significant cardiovascular disease Other protocol defined inclusion/exclusion criteria could apply
Wir empfehlen Ihnen dringend, sich an Bristol Myers Squibb zu wenden, um Nebenwirkungen (unerwünschte Ereignisse) zu melden.
Nebenwirkungen (unerwünschte Ereignisse) und andere meldepflichtige Ereignisse werden hier definiert
Nebenwirkungen (unerwünschte Ereignisse) oder Produktqualitätsbeschwerden melden: Medizinische Information